These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37370140)

  • 1. LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer.
    Dey G; Bharti R; Braley C; Alluri R; Esakov E; Crean-Tate K; McCrae K; Joehlin-Price A; Rose PG; Lathia J; Gong Z; Reizes O
    J Ovarian Res; 2023 Jun; 16(1):122. PubMed ID: 37370140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51.
    Tao L; Zhou Y; Pan X; Luo Y; Qiu J; Zhou X; Chen Z; Li Y; Xu L; Zhou Y; Zuo Z; Liu C; Wang L; Liu X; Tian X; Su N; Yang Z; Zhang Y; Gou K; Sang N; Liu H; Zou J; Xiao Y; Zhong X; Xu J; Yang X; Xiao K; Liu Y; Yang S; Peng Y; Han J; Cen X; Zhao Y
    Nat Commun; 2023 Nov; 14(1):7430. PubMed ID: 37973845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
    Cho HY; Kim YB; Park WH; No JH
    Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
    Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.
    Mukhopadhyay A; Elattar A; Cerbinskaite A; Wilkinson SJ; Drew Y; Kyle S; Los G; Hostomsky Z; Edmondson RJ; Curtin NJ
    Clin Cancer Res; 2010 Apr; 16(8):2344-51. PubMed ID: 20371688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
    Amin O; Beauchamp MC; Nader PA; Laskov I; Iqbal S; Philip CA; Yasmeen A; Gotlieb WH
    BMC Cancer; 2015 Oct; 15():817. PubMed ID: 26510816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
    Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
    Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.
    Joshi PM; Sutor SL; Huntoon CJ; Karnitz LM
    J Biol Chem; 2014 Mar; 289(13):9247-53. PubMed ID: 24554720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
    Johnson N; Johnson SF; Yao W; Li YC; Choi YE; Bernhardy AJ; Wang Y; Capelletti M; Sarosiek KA; Moreau LA; Chowdhury D; Wickramanayake A; Harrell MI; Liu JF; D'Andrea AD; Miron A; Swisher EM; Shapiro GI
    Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17041-6. PubMed ID: 24085845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
    Blanc-Durand F; Yaniz-Galende E; Llop-Guevara A; Genestie C; Serra V; Herencia-Ropero A; Klein C; Berton D; Lortholary A; Dohollou N; Desauw C; Fabbro M; Malaurie E; Bonichon-Lamaichhane N; Dubot C; Kurtz JE; de Rauglaudre G; Raban N; Chevalier-Place A; Ferron G; Kaminsky MC; Kramer C; Rouleau E; Leary A
    Gynecol Oncol; 2023 Apr; 171():106-113. PubMed ID: 36868112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
    AlHilli MM; Becker MA; Weroha SJ; Flatten KS; Hurley RM; Harrell MI; Oberg AL; Maurer MJ; Hawthorne KM; Hou X; Harrington SC; McKinstry S; Meng XW; Wilcoxen KM; Kalli KR; Swisher EM; Kaufmann SH; Haluska P
    Gynecol Oncol; 2016 Nov; 143(2):379-388. PubMed ID: 27614696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.
    Xu Z; Li X; Li H; Nie C; Liu W; Li S; Liu Z; Wang W; Wang J
    Oncogene; 2020 Nov; 39(47):7051-7062. PubMed ID: 32989256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1-Dependent and Independent Recruitment of PALB2-BRCA2-RAD51 in the DNA Damage Response and Cancer.
    Foo TK; Xia B
    Cancer Res; 2022 Sep; 82(18):3191-3197. PubMed ID: 35819255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of homologous recombination sensitizes human tumor cells to IGF-1R inhibition.
    Lodhia KA; Gao S; Aleksic T; Esashi F; Macaulay VM
    Int J Cancer; 2015 Jun; 136(12):2961-6. PubMed ID: 25388513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.
    Choi YE; Battelli C; Watson J; Liu J; Curtis J; Morse AN; Matulonis UA; Chowdhury D; Konstantinopoulos PA
    Oncotarget; 2014 May; 5(9):2678-87. PubMed ID: 24798692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.